See the article here:
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh